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Abstract
Background: Radiation therapy is a palliative treatment modality for canine osteosarcoma, with transient improvement
in analgesia observed in many cases. However there is room for improvement in outcome for these patients. It is possible
that the addition of sensitizing agents may increase tumor response to radiation therapy and prolong quality of life.
Epidermal growth factor receptor (EGFR) expression has been documented in canine osteosarcoma and higher EGFR
levels have been correlated to a worse prognosis. However, effects of EGFR inhibition on radiation responsiveness in
canine osteosarcoma have not been previously characterized. This study examined the effects of the small molecule EGFR
inhibitor erlotinib on canine osteosarcoma radiation responses, target and downstream protein expression in vitro.
Additionally, to assess the potential impact of treatment on tumor angiogenesis, vascular endothelial growth factor (VEGF)
levels in conditioned media were measured.
Results: Erlotinib as a single agent reduced clonogenic survival in two canine osteosarcoma cell lines and enhanced the
impact of radiation in one out of three cell lines investigated. In cell viability assays, erlotinib enhanced radiation effects
and demonstrated single agent effects. Erlotinib did not alter total levels of EGFR, nor inhibit downstream protein kinase B
(PKB/Akt) activation. On the contrary, erlotinib treatment increased phosphorylated Akt in these osteosarcoma cell lines.
VEGF levels in conditioned media increased after erlotinib treatment as a single agent and in combination with radiation
in two out of three cell lines investigated. However, VEGF levels decreased with erlotinib treatment in the third cell line.
Conclusions: Erlotinib treatment promoted modest enhancement of radiation effects in canine osteosarcoma cells, and
possessed activity as a single agent in some cell lines, indicating a potential role for EGFR inhibition in the treatment of a
subset of osteosarcoma patients. The relative radioresistance of osteosarcoma cells does not appear to be related to EGFR
signalling exclusively. Angiogenic responses to radiation and kinase inhibitors are similarly likely to be multifactorial and
require further investigation.
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Background
Osteosarcoma (OSA) is the most common primary bone
tumor of the domestic dog, occurring predominantly in
large breeds, and accounting for up to 85 % of skeletal
tumors in this species [1]. Local tumor growth causes se-
vere pain and lameness secondary to bone lyses, prolifer-
ation or both, and eventual metastasis from OSA to the
lungs and other locations occurs in the vast majority of
cases [1]. Surgical removal of the primary tumor, either
by amputation of the affected limb or by limb-sparing
surgery, followed by adjuvant chemotherapy is consid-
ered the standard of care for canine OSA. However, sur-
gery may be contraindicated in dogs with preexisting
orthopedic or neurologic disease, may not be elected by
owners, or may not be feasible in cases of tumors affect-
ing the axial skeleton. Thus, there is increasing interest
in treating the primary tumor by utilizing external beam
radiation therapy (RT) for dogs with OSA. Radiation
therapy has mainly been applied in palliative settings to
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provide analgesia and improve quality of life for canine
OSA patients. Most reports in the veterinary literature
describe radiation protocols consisting of two to four
treatments (fractions), delivering total doses of 16 to 32
Gray (Gy) [2]. Although pain control is achieved in ap-
proximately 70–90 % of treated dogs, responses seen
with palliative RT protocols are transient, with clinical
improvement lasting approximately 2 to 4 months [2].
Treatment failure is associated with recurrent primary
tumor growth and therefore novel strategies to improve
the response to RT for canine OSA may translate into
better clinical outcomes for these patients. Pre-clinical
work conducted in vitro using cell lines has indicated
that canine OSA is a moderately radioresistant tumor,
with a high mean surviving fraction after treatment with
2 Gy [3]. Increasing the sensitivity of OSA cells to ioniz-
ing radiation could enhance the effects of RT, possibly
improving patient outcomes.
Advances in molecular biology have resulted in the
identification of several pathways involved in the patho-
genesis and progression of cancer, which can be utilized
as therapeutic targets. The epidermal growth factor re-
ceptor (EGFR) is a transmembrane receptor tyrosine
kinase (RTK) involved in signaling for cell growth, pro-
liferation, invasion and survival [4]. Over-expression and
constitutive activation of EGFR have been found in nu-
merous human cancers, including breast, lung and head
and neck carcinomas [5]. In veterinary oncology, EGFR
expression has been identified in various epithelial ma-
lignancies, including canine lung, nasal, mammary and
transitional cell carcinoma, and feline squamous cell car-
cinoma (SCC) [6–11]. Additionally, higher expression
levels of EGFR have been associated with more aggres-
sive cancer behavior [6–11]. The role of aberrant activa-
tion of EGFR in the pathogenesis of mesenchymal
tumors, such as OSA, is less well defined. Expression of
EGFR has been documented in human [12, 13] and ca-
nine OSA [14], and correlated with a worse prognosis,
indicating that EGFR may play a role in OSA tumor
biology and therefore EGFR pathway inhibition could
represent a viable treatment option for OSA. In vitro
targeting of EGFR with RTK inhibitors has been
reported in the veterinary literature, with successful in-
hibition of cell proliferation and growth of canine mam-
mary carcinoma and OSA cell lines [15, 16], further
supporting EGFR inhibition as a possible treatment ap-
proach for canine OSA.
The combining of RT with cytotoxic chemotherapy
and/or more targeted cancer therapeutics has been
widely investigated in human oncology, with the goal of
improving the effectiveness of radiation (radiosensitiza-
tion) [4]. Targeting the EGFR pathway is an attractive
approach for radiosensitization for multiple reasons.
EGFR inhibitors commonly produce a cytostatic effect
with arrest in the G1 phase of the cell cycle, which can
prevent tumor cell repopulation post-radiation [17, 18].
Additionally, exposure of tumor cells to ionizing radi-
ation can activate EGFR independently from ligands,
contributing to tumor radioresistance [4, 19, 20]. There-
fore, neutralizing this tumor response to radiation by
inhibiting EGFR signaling could maintain tumor sensi-
tivity. Erlotinib is a selective inhibitor of EGFR tyrosine
kinase, which blocks cell cycle progression at the G1
phase and induces apoptosis of select human carcinoma
cells in vitro [21]. Erlotinib has been used in the treat-
ment of several human malignancies, and is approved
for the treatment of non-small-cell lung cancer (NSCLC)
and advanced pancreatic cancer in the United States. In
human oncology, the use of erlotinib as a radiosensitizer
has been successful in pre-clinical work [22–24], and
has shown promising results in phase I/II clinical trials
for head and neck SCC and NSCLC [25–27].
The effects of EGFR activation are exerted via subse-
quent activation of multiple downstream intracellular
signaling pathways, including the phosphatidylinositol-3-
kinase (PI3K) signaling cascade that culminates with ac-
tivation of the serine/threonine kinase Protein kinase B
(PKB/Akt). Upon stimulation of EGFR, PI3K is activated
and generates phosphatidylinositol-3,4,5-trisphosphate
(PIP3), which in turn acts as a second messenger for ac-
tivation of Akt. Upon activation, Akt phosphorylates nu-
merous downstream cytoplasmic and nuclear substrates,
ultimately resulting in enhanced cell survival, prolifera-
tion, and inhibition of apoptosis [28, 29]. Radiation treat-
ment may lead to enhancement of this signaling
pathway in cancer cells as a response to treatment. Ex-
posure of human carcinoma and glioblastoma cells to
radiation in vitro activated Akt, and promoted increased
cell survival and proliferation [28–30], through activa-
tion of EGFR via a ligand-independent mechanism. In
these studies, increased levels of phosphorylated-Akt (p-
Akt) were found within 4 h of RT, and inhibition of Akt
enhanced radiosensitivity of tumor cells [28–30]. It is
possible that similar EGFR activation and secondary in-
creases in p-Akt levels could be seen following RT of ca-
nine OSA. Furthermore, evaluating the PI3K/Akt
pathway could potentially serve as a surrogate biomarker
for inhibition of upstream receptor targets like EGFR
after treatment with erlotinib or other agents.
This study investigated the effects of erlotinib alone
and in combination with RT on canine OSA cell lines.
Therapeutic effects were evaluated by clonogenic sur-
vival, cell viability, and the expression of target and
downstream proteins. Finally, because one of the mecha-
nisms of action for both radiation and EGFR inhibition
has been shown to be inhibition of angiogenesis, we in-
vestigated the impact of treatment on levels of the po-
tent angiogenesis factor vascular endothelial growth
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factor (VEGF) secreted by OSA cells into conditioned
media. Dose dependent erlotinib single agent activity
was observed in all cell lines. Erlotinib provided en-
hancement of radiation effects on Dharma OSA cells at
2, 4 and 6 Gy doses, which are lower doses than the
commonly used 8 Gy per fraction dose utilized in most
palliative radiation protocols for osteosarcoma. Erlotinib
increased VEGF levels in conditioned media and this




Canine osteosarcoma cell lines D17, Abrams and Dharma
were used. D17 cells were obtained from Sigma-Aldrich/
European Collection of Cell Cultures (ECACC). Abrams
cells were a generous gift from Mike Huelsmeyer at the
University of Wisconsin. Both D17 and Abrams cell lines
have been utilized on several published studies and have
been characterized as canine OSA cells based on morph-
ology and xenograft analysis [31]. Dharma cells were iso-
lated and adapted to culture from a clinical case by Dr.
Anthony Mutsaers, and validated as OSA by histopath-
ology evaluation of tumors produced from successful
xenograft outgrowth after implantation in immunocom-
prised (nude) mice. All cells were grown in Dulbecco’s
modified Eagle’s media (Hyclone DMEM - Fisher Scien-
tific- Ottawa, ON, Canada) supplemented with 10 % fetal
bovine serum (Life Technologies, Burlington, ON,
Canada) and 1 % penicillin/streptomycin (BioWhittaker,
Mississauga, ON, Canada). All cell cultures were main-
tained at 37 °C and 5 % CO2 in a humidified incubator.
Radiation therapy
Cell culture plates were irradiated at ambient temperature
and pressure, at a rate of 400 monitor units/min utilizing
a 6-MV linear accelerator (Clinac IX System, Varian Med-
ical Systems, Inc., Palo Alto, CA, USA). Cell culture dishes
were placed between two solid water-equivalent plates,
with thickness of 4.5 cm on top and 5 cm on the bottom.
The dose distribution for this set up was medical physicist
verified. Control cell culture plates were transported to
the radiation therapy area but kept outside the radiation
vault during treatments.
Clonogenic survival
Cells were seeded into six-well plates (D17 and Abrams
at 500 cells/well, and Dharma at 1,500 cells/well) with
3 ml of media. After 24 h, the media of all wells was re-
placed and erlotinib (SelleckChem, Houston, TX, USA)
at 10 μM was added to treatment group wells. Erlotinib
was diluted in dimethyl sulfoxide (DMSO) resulting in a
final concentration of 0.04 % DMSO in each well. After
incubation for 4 to 6 h, doses of 0, 2, 4, 6, 8 and 10 Gy
of radiation were administered to individual plates. Col-
ony formation was monitored daily and the experiment
stopped after 10 to 14 days, before the control colonies
became confluent. Cells were stained with 0.5 % crystal
violet in 20 % methanol for 30 minutes, then washed
gently twice with tap water [32]. Colonies were visual-
ized by light microscopy and counted. A colony was de-
fined as an aggregate of ≥ 50 cells. The cell surviving
fraction, normalized for plating efficiency, was deter-
mined for each radiation dose. All experiments were re-
peated three times.
Cell viability
To assess cell viability, Resazurin Cell Viability Kit
(Sigma-Aldrich, Oakville, ON, Canada) was used at a
concentration of 5.0 mg/ml. Cells were seeded into 96-
well plates (D17 and Abrams at 500 cells/well, and
Dharma at 2,000 cells/well), and settled for 24 h at 37 °C
and 5 % CO2 [33]. Erlotinib was administered at 10 μM
and 40 μM, plates were incubated for 4 to 6 h, and doses
of 0, 2, 4, 6, 8 and 10 Gy of radiation were delivered to
individual plates. After 72 h, 100 μl of Resazurin solution
was pipetted into each well. After the solution in wells
changed in color, absorbance readings were obtained
from a Synergy 2 spectrophotometer (BioTek, Winooski,
VT, USA), at an excitation wavelength of 570 nm and
emission wavelength of 600 nm. Relative viable cell
number was assessed by means of sextuplicate wells for
each erlotinib concentration and corresponding control
group, and each experiment was repeated three times.
Absorbance values were corrected for media only read-
ings in sextuplicate wells.
Protein detection
Cells were seeded into six-well plates (D17 and Abrams
at 150,000 cells/well, and Dharma at 200,000 cells/well)
and settled for 24 h at 37 °C and 5 % CO2. The media of
all wells was replaced to divide groups into erlotinib at
10 μM or control, followed by incubation for 4 to 6 h.
Plates were irradiated with a 2 Gy dose or kept in the ra-
diation control room during treatment. Cells were lysed
in ice cold buffer (Cell Signaling technology, Whitby,
ON, Canada) containing aprotinin, phenylmethanesulfo-
nyl fluoride and a phosphatase inhibitor cocktail, and
collected 0.25, 0.5, 1, 2, 24 and 48 h post radiation, and
placed immediately on ice. Cell lysis buffer additives
were obtained from Sigma-Aldrich (Oakville, ON,
Canada). Equal amounts of protein were separated by
SDS polyacrylamide gel electrophoresis and transferred
to a polyvinyl difluoride membrane (Roche Diagnostics
Corporation, Indianapolis, IN, USA). Membranes were
hybridized to an appropriate primary antibody and
horseradish peroxidase (HRP) conjugated secondary
antibody, then visualized using the Bio-Rad Chemi-Doc
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system (Universal Hood III). Primary antibody against β-
actin, EGFR, Akt and p-Akt were purchased from Cell
Signaling Technology (Whitby, ON, Canada). The sec-
ondary antibodies, HRP-conjugated goat anti-rabbit IgG
were obtained from Santa Cruz Biotechnology Inc. (Dal-
las, TX, USA).
VEGF levels
Conditioned media was collected and pooled from sextu-
plicate wells treated with erlotinib at 10 μM, with or with-
out radiation treatment at 2 Gy and 8 Gy at 72 h. Levels
of VEGF were quantified using the Quantikine Canine
VEGF ELISA Kit (R&D Systems, Minneapolis, MN, USA),
following the manufacturer’s instructions [33]. The optical
density of the standard solutions was plotted against their
corresponding concentrations to generate a standard
curve and allow determination of sample VEGF concen-
trations. Absorbance was read at 450 nm and corrected by
subtracting readings at 540 nm, as per manufacturer
recommendation.
Statistical analysis
Statistical analyses were performed with Graph-Pad
Prism 5 software (GraphPad Software, Inc., La Jolla, CA,
USA). For clonogenic survival and cell viability assays, a
two-way analysis of variance (ANOVA) with Sidak
method for multiple comparisons was used to determine
whether erlotinib treatment had an effect in clonogenic
survival and cell viability compared to radiation only
treatment groups. For VEGF levels, a one-way ANOVA
was used to determine whether treatment with erlotinib
and/or radiation had an effect on VEGF concentrations
compared to control groups. To account for changes in
cell number that may influence VEGF levels, readings
were normalized to cell viability of respective wells, as
measured by Resazurin assay. Overall significance was
set at p < 0.05.
Results
Effects of erlotinib and radiation on clonogenic survival
Erlotinib showed single agent activity through reduction in
clonogenic survival in 2 out of 3 cell lines: p < 0.0001 for
Dharma and p = 0.0003 for D17 (Fig. 1). No effect was seen
in Abrams cells. Radiation administered at doses ranging
from 2 to 10 Gy demonstrated a dose dependent reduction
in clonogenic survival, as expected, in all 3 OSA cell lines
examined (Fig. 2). Treatment with erlotinib four to six
hours prior to radiation therapy resulted in a significant re-
duction in clonogenic survival of Dharma OSA cells for
the lower radiation doses of 2 Gy (p < 0.0001), 4 Gy (p <
0.0001) and 6 Gy (p = 0.0127). This effect was lost at the
higher radiation doses that resulted in a lower survival frac-
tion from radiation treatment alone. In this cell line the
shape of the survival curve for the “erlotinib” group had a
more narrow shoulder compared to the “control” curve
(Fig. 2), indicating the potential for reduced sublethal dam-
age repair in these erlotinib treated cells. Enhancement of
radiation effects was not observed in D17 (p = 0.39) and
Abrams (p = 0.71) OSA cells.
Effects of erlotinib and radiation on cell viability
Cell viability assays were assessed 72 h post-radiation
(Fig. 3). Radiation administered at doses ranging from 2 to
10 Gy demonstrated dose dependent reductions in cell via-
bility for 2 out of 3 OSA cell lines. The viability of Dharma
cells was less impacted by radiation but interestingly, these
cells were more sensitive to single agent erlotinib on cell
viability assays, with statistically significant reductions in
cell viability for all erlotinib treated groups (p < 0.0001), as
shown in Fig. 3. Given the lack of response seen in 2 cell
lines with erlotinib at 10 μM, a higher dose of 40 μM was
tested. The viability of all 3 cell lines was reduced by this
higher, but clinically/pharmacologically less relevant con-
centration of erlotinib. Addition of erlotinib at 40 μM re-
sulted in decreased cell viability compared to radiation
alone for all cell lines, however these effects were not sta-
tistically significant for Abrams cells at radiation doses
above 4 Gy (p = 0.14). Treatment with erlotinib at the
lower 10 μM dose further decreased viability in radiated
Dharma cells (p ≤ 0.0002), but failed to provide enhance-
ment of radiation effects for Abrams (p = 0.25) and D17
cells (p = 0.38).
Expression of target proteins
Western blot analyses detected endogenous expression
of EGFR, total Akt and p-Akt in all three OSA cell
lines investigated. Treatment with erlotinib, with or
without radiation, increased levels of p-Akt in
Dharma and D17 cells at 0.25, 0.5, 1, 2 and 24 h after
radiation treatment (Fig. 4). Levels of p-Akt showed
Fig. 1 Effects of single agent erlotinib on clonogenic survival. Canine
OSA cells treated with erlotinib at 10 μM for 4-6 h (“erlotinib”).
Experiments were repeated three times and average of results
are shown. Erlotinib showed single agent activity through reduction in
clonogenic survival in 2 out of 3 cell lines. * p < 0.05 indicates statistical
significant reduction in clonogenic survival compared to control
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minimal variation among treatment groups in Abrams
cells. Total Akt and EGFR were detected in all cell
lines at all time points and treatment combinations,
with no consistent variations seen among treatment
groups.
Effects of erlotinib and radiation on VEGF levels
Secreted VEGF was detected in the conditioned media
from all three canine OSA cell lines investigated
(Table 1). Changes in VEGF levels compared to control
occurred more consistently after combination treatment
with radiation doses of 2 and 8 Gy (Fig. 5, Table 2).
Interestingly, conditioned media from Dharma and
Fig. 2 Clonogenic survival curves. Canine OSA cells were treated with
radiation only (“control”) or in combination with erlotinib at 10 μM
(“erlotinib”) given 4-6 h before radiation. Experiments were repeated
three times and average of results are shown. Survival fractions are
plotted on a log-scale. Erlotinib treatment resulted in statistically
significant reduction in cell survival of Dharma cells for radiation
doses of 0, 2, 4 and 6 Gy, and statistically significant reduction
in cell survival for D17 cells at 0 Gy, but did not promote enhancement
of radiation effects for D17 or Abrams cell lines. *p < 0.05 indicates
statistical significant reduction in clonogenic survival compared
to 1control at the corresponding radiation dose
Fig. 3 Cell viability assays 72 h post-radiation. Cells were treated
with either radiation only (“control”), or radiation plus erlotinib at
10 μM or 40 μM. Experiments were repeated three times and
average of results are shown. Addition of erlotinib resulted in
statistically significant decreases in cell viability for Dharma cells
at 10 μM, and for all cell lines at 40 μM dose. Enhancement of
radiation effects were less pronounced at 10 μM, as seen in Dharma
cells. *p <0.05 indicates statistically significant reduction in percentage
of viable cells compared to control group at the corresponding
radiation dose
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Abrams cells showed increases in VEGF levels, whereas
D17 cells showed decreases. Exposure to radiation at
8 Gy provided a significant reduction in VEGF levels for
D17 cells (p < 0.09), but no other statistically significant
changes were observed.
Discussion
The interaction of ionizing radiation with cells promotes
both direct and indirect effects. Energy absorption can
induce direct damage of molecules, however most of the
energy deposited within cells is absorbed by water, gen-
erating free radicals. These are highly reactive molecules
that can cause breakage of deoxyribonucleic acid (DNA)
strands. If damaged DNA is not successfully repaired, ei-
ther cell death or chromosomal aberrations may occur
upon cell division [34]. With the exception of a few cell
types, such as lymphocytes, that undergo apoptosis
shortly after radiation exposure, most cell death second-
ary to irradiation takes place by mitotic catastrophe [34].
Rapidly proliferating cells have a high rate of cell div-
ision, and will therefore be more sensitive to radiation
effects, or at least manifest the consequences of radi-
ation damage sooner than slower dividing cell popula-
tions. However, cells that are proficient in DNA repair
will be more resistant to radiation cytotoxicity.
After irradiation, cells may continue to be metabolically
active (which is detectable in viability assays), but they may
lose the capacity to undergo normal cell division and main-
tain continued reproductive ability [34]. Clonogenic sur-
vival assays after RT assess a cell’s ability to survive
treatment, preserve cell division and repopulate the tumor,
and therefore these assays provide an important in vitro
assessment of potential therapeutic success. Radiation
dose-response cell survival curves based on colony forma-
tion assays represent the total cumulative clonogenic out-
growth. The shoulders of these curves illustrate the
capability of cells to repair sublethal DNA damage, and a
wider shoulder indicates more efficient repair and subse-
quent repopulation, keeping clonogenic survival high. Cell
survival curves in this current study were in agreement
with previously reported RT dose-response curves for ca-
nine OSA cells, displaying a wide shoulder and moderate
radioresistance [3]. Treatment with erlotinib provided sta-
tistically significant reductions in cell survival of Dharma
cells at doses of 2, 4 and 6 Gy compared to control groups
(Fig. 2). The radiosensitization effects of erlotinib are pro-
posed to be, at least in part, secondary to cell cycle arrest in
the G1 phase [4, 17, 18]. Cells in G1 phase are less radio-
sensitive than cells in G2 or M phases of the cell cycle,
which makes radiosensitization by EGFR inhibitors appear
counterintuitive. However, arrest in G1 also provides a cy-
tostatic effect that prevents tumor cell repopulation be-
tween fractions of RT, still potentially enhancing the
efficacy of a radiation protocol [4, 17, 18, 34]. It is possible
that the sequence of treatment with a targeted EGFR in-
hibitor may play a role in radiosensitization. In this study
cells were pre-treated with erlotinib 4 h prior to radiation,
and drug treatment only after radiation was not investi-
gated. Figure 2 also illustrates a narrowing of the shoulder
in the cell survival curve for Dharma cells, indicating that
decreased repopulation may have contributed to enhance-
ment of radiation effects seen in this cell line. Colony
Fig. 4 Western blot analysis of EGFR and downstream proteins. EGFR, total Akt and p-Akt were detected in all OSA cell lines investigated. Higher
levels of p-Akt were seen after treatment with erlotinib, with or without radiation, in Dharma and D17 cells at 0.25, 0.5, 1, 2 and 24 hours
Table 1 Median VEGF concentration in conditioned media 72 h
post-radiation (pg/mL)
Abrams Dharma D17
Control 57.8 ± 36.4 476.7 ± 177.2 143.7 ± 60.1
Erlotinib 144.1 ± 63.4 413.9 ± 204.6 157.6 ± 91.4
2Gy 34.8 ± 20.4 465.8 ± 181.1 139.2 ± 57.1
8Gy 21.1 ± 7.7 447.3 ± 162.9 135.5 ± 37.8
2Gy + Erlotinib 130.4 ± 55.6 490.9 ± 225.3 148.9 ± 73.3
8Gy + Erlotinib 52.8 ± 15.9 398.8 ± 92 163.4 ± 54.9
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formation assays in the present study showed no radiosen-
sitizing effects of erlotinib on Abrams or D17 cells. Finally,
it is also unknown whether Abrams cells, which appear to
be more inherently resistant to erlotinib based on the re-
sults of Fig. 1, fail to undergo any G1 arrest after treatment
with this drug.
Cell viability assays, such as the Resazurin assay, rely on
bioreduction of the reagent dye by metabolically active
cells, providing an indirect determination of cell viability.
Such assays may not reflect the later death following cell di-
visions that is reflected in clonogenic survival assay results.
Nevertheless, cell viability was assessed in the present study
to investigate possible radiation enhancing effects of erloti-
nib by multiple mechanisms (Fig. 3). Abrams cells showed
marked radiation dose-dependent reduction of cell viability,
but moderate radioresistance on clonogenic survival assays.
This discrepancy could potentially be explained by efficient
repopulation. Abrams cells are very fast growing with a
doubling time of approximately 17 h. Therefore at 72 h
post-radiation, multiple cell divisions would likely have oc-
curred, with consequent mitotic deaths, and corresponding
low cell viability on Resazurin assays. Any surviving clones
would have then undergone repopulation, resulting in the
cell survival curves shown in Fig. 2. It could be concluded
that erlotinib failed to prevent repopulation of Abrams
cells, at least at the 10 μM dose. These findings were in
contrast to Dharma cells, which showed less pronounced
dose-dependent effects of radiation on cell viability assays,
yet radiation demonstrated consistent suppression of clono-
genic survival. Dharma cells have a doubling time of 34 h.
Thus, after only 72 h the cytotoxic effects of RT may have
been undetectable, as a significant proportion of cells have
not yet undergone mitosis. D17 cells showed moderate ra-
diation dose-response sensitivity on cell viability assays,
which was more pronounced on clonogenic survival assays.
Interestingly, the doubling time of D17 cells is 23 h, which
is longer than Abrams cells but shorter than Dharma cells.
Erlotinib treatment promoted cytotoxic effects as a single
agent at 10 μM for Dharma and D17 cells, and at 40 μM
for all three cell lines investigated. Additionally, enhance-
ment of radiation effects was seen at the 40 μM dose for
all cell lines on cell viability assays. In addition to dosing,
the order of treatment and period of exposure can influ-
ence the effects of combination therapy. In this study erlo-
tinib was administered to cells 4 to 6 h prior to RT, and
remained in the media until the end of experiments, in an
effort to mimic how RTK inhibitors are used clinically. It is
possible that a more prolonged period of erlotinib
Fig. 5 Concentration of VEGF in conditioned media 72 h post-radiation. VEGF levels are expressed as a ratio of change from control. *p < 0.05 in-
dicates statistical significant change. Changes in VEGF levels were variable among cell lines, but significant changes occurred most consistently
with combination RT plus erlotinib treatment
Table 2 Median VEGF concentration 72 h post-radiation
normalized to cell viability (pg/mL) * indicates significant
change from control (p < 0.05)
Abrams Dharma D17
Control 0.57 4.76 0.76
Erlotinib 1.22* 7.66 0.75
2Gy 0.37 5.22 0.61
8Gy 0.44 5.67 0.49*
2Gy + Erlotinib 1.32* 9.96 0.56
8Gy + Erlotinib 1.14* 9.32* 0.38*
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exposure prior to RT would have promoted enhancement
of RT effects on D17 and Abrams cells. Nevertheless, the
cytotoxic and radiation enhancing effects of erlotinib dem-
onstrated in this current study support in vivo evaluation
of EGFR inhibition as a possible treatment strategy for a
subset of canine OSA cases. As erlotinib-induced enhance-
ment of RT effects on cell viability were more pronounced
at RT doses of 2 and 4 Gy, it can be expected that EGFR
inhibition might be more effective in potentiating the ef-
fects of hyperfractionated curative protocols as opposed to
the currently used palliative RT protocols. Further investi-
gations of the ideal dosing, timing of drug exposure and
RT protocol, utilizing additional OSA cells, xenograft
models and other EGFR inhibitors is recommended to im-
prove our understanding of potential radiosensitization ef-
fects of EGFR targeting in canine OSA. Given that not all
patients are likely to benefit from this therapy, evaluation
of EGFR expression and pathway activation for individual
tumors could be investigated further as potential bio-
markers of treatment response.
Protein analysis by Western blot confirmed EGFR ex-
pression in all three cell lines, with no variation in levels
among treatment groups consistently throughout the
time points examined. In contrast to antibody therapeu-
tics such as cetuximab that can impact receptor traffick-
ing, the small molecule kinase inhibitor erlotinib may
not be expected to cause decreased total EGFR with sig-
naling inhibition. The protein Akt was evaluated as a po-
tential downstream indicator of EGFR kinase signaling
inhibition. Activation of Akt post-radiation has been
documented in human carcinoma and glioblastoma cells
in vitro [28–30]. In the current study, increased levels of
p-Akt post RT were not observed. It is possible that RT
treatment does not activate the EGFR pathway in canine
OSA cells as it occurs with human carcinoma and glio-
blastoma cells [28–30]. Interestingly however, increased
levels of p-Akt were observed after erlotinib was used as
a single agent or in combination with RT in D17 and
Dharma cells. Increased levels of p-AKT may contribute
to cell survival, and this was an unexpected finding with
erlotinib treatment. These findings in the context of
EGFR inhibitor use suggest that the EGFR pathway may
not be exclusively responsible for the radioresistance of
canine OSA, and illustrate that signaling responses after
molecular targeting agents may be multifaceted. Other
signaling cascades downstream of EGFR not investi-
gated herein, such as the mitogen-activated protein
kinases (MAPK/erk) pathway, could also be involved
in the cytotoxic effects of erlotinib. Further evaluation
of signaling events post RT and EGFR inhibition for
canine OSA cells are warranted, as such studies could
shed more light on the potential mechanisms involved
in this treatment and improve targeted therapeutic
strategies for this cancer.
The amount of VEGF secreted by OSA cells constitu-
tively and after treatment with RT, erlotinib and combina-
tions was quantified in this study. Increased serum VEGF
levels in dogs with OSA has been correlated with de-
creased disease free intervals [35], and constitutive VEGF
levels have previously been observed in canine OSA cells
[33]. Dose-dependent increases in VEGF levels after RT
have been documented in human glioblastoma cells and
in lung cancer mouse xenografts [36, 37], and proposed to
be associated with radioresistance. In the veterinary litera-
ture, RT up-regulated VEGF production in a melanoma
cell line in a dose-dependent manner [38], but no changes
in VEGF levels post- radiation were seen in a mast cell
tumor cell line [39]. There are also correlations between
the EGFR and VEGF pathways, as these share parallel and
reciprocal downstream signaling mechanisms, and exert
direct and indirect effects on tumor cells that contribute
to cancer progression [40]. Additionally, epidermal growth
factor, an important ligand for EGFR, also drives VEGF
expression, and an overactive VEGF pathway plays a role
in tumor resistance to treatment with EGFR inhibitors
[40, 41]. Treatment with gefitinib, a selective EGFR RTK,
resulted in decreased cell proliferation and decreased
microvascular density and VEGF levels in murine renal
cell carcinoma [42].
In the present study, VEGF production was not up-
regulated after RT, and statistically significant decreased
levels were seen by D17 cells after 8 Gy. Treatment with
RTK inhibitors can modulate VEGF levels in an off-
target manner. Increased VEGF levels have been found
in vitro after canine OSA cells were treated with masiti-
nib, a RTK inhibitor targeting c-Kit and platelet-derived
growth factor receptor [33]. In our study, statistically
significant changes in VEGF levels occurred more con-
sistently after combination therapy. Additionally, D17
cells showed decreases whereas Dharma and Abrams
cells had increases in VEGF production. This variability
in VEGF levels post tyrosine kinase inhibitor treatment
and RT illustrates the complexity of responses of indi-
vidual cancers to cytotoxic stimuli, and the need for fur-
ther investigation of angiogenic responses to anti-cancer
therapeutics.
Conclusions
Erlotinib treatment promoted modest enhancement of radi-
ation effects in canine OSA cells, and showed activity as a
single agent, indicating a possible role of EGFR inhibition
in the treatment of a subset of OSA patients. Radioresis-
tance of OSA cells does not appear to depend exclusively
on EGFR signaling. Expanding research into signaling
cascade alterations and angiogenic responses to combina-
tions of RT with RTK inhibitors are worthy of further
investigation.
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